

ACYCLOVIR OINT (CCHP2017)

Products Affected

Step 2:

- *acyclovir 5 % topical ointment*

Details

Criteria	Step Therapy requires trial of one (1) of the following: oral generic acyclovir, oral generic famciclovir, oral generic valacyclovir.
-----------------	---

ALPHAGAN (CCHP2017)

Products Affected

Step 2:

- ALPHAGAN P 0.1 % EYE DROPS

Details

Criteria	Step Therapy requires trial of brimonidine 0.15%.
-----------------	---

ANAPHYLAXIS_NVT 2015

Products Affected

Step 2:

- *epinephrine 0.15 mg/0.15 ml auto-injector (for 33 to 66 lb patients)*
- *epinephrine 0.3 mg/0.3 ml injection, injector-auto*

Details

Criteria	
	Step Therapy requires trial of EPIPEN or EPINEPHRINE 0.15MG/0.3ML AUTO-INJECTOR in previous 120 days.

ANTIDEPRESSANT_NVT 2017

Products Affected

Step 2:

- DESVENLAFAXINE ER 100 MG TABLET,EXTENDED RELEASE 24 HR
- DESVENLAFAXINE ER 50 MG TABLET,EXTENDED RELEASE 24 HR
- DESVENLAFAXINE FUMARATE ER 100 MG TABLET, EXTENDED RELEASE 24 HR
- DESVENLAFAXINE FUMARATE ER 50 MG TABLET, EXTENDED RELEASE 24 HR
- *duloxetine 40 mg capsule, delayed release*
- EMSAM 12 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 6 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- FETZIMA 120 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK
- FETZIMA 20 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 40 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 80 MG CAPSULE,EXTENDED RELEASE
- *fluvoxamine er 100 mg capsule, extended release 24 hr*
- *fluvoxamine er 150 mg capsule, extended release 24 hr*
- MARPLAN 10 MG TABLET
- PEXEVA 10 MG TABLET
- PEXEVA 20 MG TABLET
- PEXEVA 30 MG TABLET
- PEXEVA 40 MG TABLET
- TRINTELLIX 10 MG TABLET
- TRINTELLIX 20 MG TABLET
- TRINTELLIX 5 MG TABLET
- VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK
- VIIBRYD 10 MG TABLET
- VIIBRYD 20 MG TABLET
- VIIBRYD 40 MG TABLET

Details

Criteria	Step Therapy requires trial of one of the following generic SSRI's in previous 120 days: escitalopram, sertraline, fluoxetine, citalopram, paroxetine, Paxil oral solution, or fluvoxamine. If request is for duloxetine, step not required for diabetic peripheral neuropathy, fibromyalgia, or chronic musculoskeletal pain.
-----------------	--

APLENZIN_NVT 2015

Products Affected

Step 2:

- APLENZIN 174 MG
TABLET,EXTENDED RELEASE
- APLENZIN 348 MG
TABLET,EXTENDED RELEASE
- APLENZIN 522 MG
TABLET,EXTENDED RELEASE

Details

Criteria	
	Step Therapy requires trial of bupropion SR or bupropion XL in previous 120 days.

ARICEPT 23_NVT 2015

Products Affected

Step 2:

- *donepezil 10 mg disintegrating tablet*
- *donepezil 5 mg disintegrating tablet*

Details

Criteria	Step Therapy requires trial of regular donepezil 5 mg or 10mg oral tablets in previous 120 days.
-----------------	--

DEXILANT_2019

Products Affected

Step 2:

- DEXILANT 30 MG CAPSULE, DELAYED RELEASE
- DEXILANT 60 MG CAPSULE, DELAYED RELEASE

Details

Criteria
Step therapy requires trial of lansoprazole in the previous 120 days.

DIFICID_NVT

Products Affected

Step 2:

- DIFICID 200 MG TABLET

Details

Criteria
Step Therapy requires trial of vancomycin.

DPP4

Products Affected

Step 2:

- JANUMET 50 MG-1,000 MG TABLET
- JANUMET 50 MG-500 MG TABLET
- JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE
- JANUMET XR 50 MG-1,000 MG TABLET,EXTENDED RELEASE
- JANUMET XR 50 MG-500 MG TABLET,EXTENDED RELEASE
- JANUVIA 100 MG TABLET
- JANUVIA 25 MG TABLET
- JANUVIA 50 MG TABLET

Step 3:

- KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE
- KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE
- KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE
- ONGLYZA 2.5 MG TABLET
- ONGLYZA 5 MG TABLET

Details

Criteria	Step Therapy requires trial of Metformin for Januvia, Janumet, or Janumet XR in the past 120 days. Trial of both Metformin AND Janumet, Janumet XR, OR Januvia required for Onglyza or Kombiglyze XR in the past 120 days.
-----------------	--

DRY EYE OTC (CCHP 2018)

Products Affected

Step 2:

- RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE

Details

Criteria	
	Step Therapy requires trial of OTC artificial tears.

ESTRING_NVT 2016

Products Affected

Step 2:

- ESTRING 2 MG (7.5 MCG/24 HOUR) VAGINAL RING
- FEMRING 0.05 MG/24 HR VAGINAL
- FEMRING 0.1 MG/24 HR VAGINAL
- PREMARIN 0.625 MG/GRAM VAGINAL CREAM

Details

Criteria	Step Therapy requires trial of ESTRADIOL VAGINAL CREAM OR TABLET in previous 120 days.
-----------------	--

GLP1

Products Affected

Step 2:

- OZEMPIC 0.25 MG OR 0.5 MG (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR
- OZEMPIC 1 MG/DOSE (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR
- TRULICITY 0.75 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR
- TRULICITY 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR
- VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR

Details

Criteria	ST Criteria: Pending CMS Approval
----------	-----------------------------------

LAMA/LABA

Products Affected

Step 2:

- STIOLTO RESPIMAT 2.5 MCG-2.5 MCG/ACTUATION SOLUTION FOR INHALATION

Details

Criteria	
	Step Therapy requires trial of ANORO.

NASAL CORTICOSTEROIDS_NVT 2017

Products Affected

Step 2:

- BECONASE AQ 42 MCG (0.042 %) NASAL SPRAY
- *mometasone 50 mcg/actuation nasal spray*
- OMNARIS 50 MCG NASAL SPRAY
- QNASL 40 MCG/ACTUATION NASAL AEROSOL SPRAY
- QNASL 80 MCG/ACTUATION NASAL AEROSOL SPRAY
- ZETONNA 37 MCG/ACTUATION NASAL HFA INHALER

Details

Criteria	
	Step Therapy requires trial of TWO (2) formulary generic Nasal Corticosteroids. If for nasal polyps, step therapy not required for BECONASE AQ. If for prophylaxis of seasonal allergic rhinitis, step therapy not required for mometasone. If for seasonal and perennial vasomotor nonallergic rhinitis, trial of fluticasone only required for BECONASE AQ.

OPHTHALMIC ANTI-INFECTIVES_NVT 2015

Products Affected

Step 2:

- BESIVANCE 0.6 % EYE DROPS,SUSPENSION
- *gatifloxacin 0.5 % eye drops*

Details

Criteria	Step Therapy requires trial of one of the following ciprofloxacin, levofloxacin, or ofloxacinin previous 120 days.
-----------------	--

PANCREATIC ENZYMES_NVT 2015

Products Affected

Step 2:

- PANCREAZE 10,500 UNIT-35,500 UNIT-61,500 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 16,800 UNIT-56,800 UNIT-98,400 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 2,600 UNIT-6,200 UNIT-10,850 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 21,000 UNIT-54,700 UNIT-83,900 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 4,200 UNIT-14,200 UNIT-24,600 UNIT CAPSULE,DELAYED RELEASE
- PERTZYE 16,000 UNIT-57,500 UNIT-60,500 UNIT CAPSULE,DELAYED RELEASE
- PERTZYE 24,000-86,250-90,750 UNIT CAPSULE,DELAYED RELEASE
- PERTZYE 4,000 UNIT-14,375 UNIT-15,125 UNIT CAPSULE,DELAYED RELEASE
- PERTZYE 8,000 UNIT-28,750 UNIT-30,250 UNIT CAPSULE,DELAYED RELEASE
- ZENPEP 10,000 UNIT-32,000 UNIT-42,000 UNIT CAPSULE,DELAYED RELEASE
- ZENPEP 15,000 UNIT-47,000 UNIT-63,000 UNIT CAPSULE,DELAYED RELEASE
- ZENPEP 20,000 UNIT-63,000 UNIT-84,000 UNIT CAPSULE,DELAYED RELEASE
- ZENPEP 25,000 UNIT-79,000 UNIT-105,000 UNIT CAPSULE,DELAYED RELEASE
- ZENPEP 3,000 UNIT-10,000 UNIT-14,000 UNIT CAPSULE,DELAYED RELEASE
- ZENPEP 40,000 UNIT-126,000 UNIT-168,000 UNIT CAPSULE,DELAYED RELEASE
- ZENPEP 5,000 UNIT-17,000 UNIT-24,000 UNIT CAPSULE,DELAYED RELEASE

Details

Criteria	Step Therapy requires trial of CREON in previous 120 days.
-----------------	--

POLYETHYLENE GLYCOL

Products Affected

Step 2:

- AMITIZA 24 MCG CAPSULE
- AMITIZA 8 MCG CAPSULE
- LINZESS 145 MCG CAPSULE
- LINZESS 290 MCG CAPSULE
- LINZESS 72 MCG CAPSULE
- MOVANTIK 12.5 MG TABLET
- MOVANTIK 25 MG TABLET
- RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SOLUTION
- RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SYRINGE
- RELISTOR 8 MG/0.4 ML SUBCUTANEOUS SYRINGE

Details

Criteria	Step Therapy requires trial of OTC polyethylene glycol in the past 120 days.
-----------------	--

RYTARY_NVT

Products Affected

Step 2:

- RYTARY 23.75 MG-95 MG
CAPSULE,EXTENDED RELEASE
- RYTARY 36.25 MG-145 MG
CAPSULE,EXTENDED RELEASE
- RYTARY 48.75 MG-195 MG
CAPSULE,EXTENDED RELEASE
- RYTARY 61.25 MG-245 MG
CAPSULE,EXTENDED RELEASE

Details

Criteria	
	Step Therapy requires trial of carbidopa/levodopa ER tab.

SGLT2

Products Affected

Step 2:

- INVOKAMET 150 MG-1,000 MG TABLET
- INVOKAMET 150 MG-500 MG TABLET
- INVOKAMET 50 MG-1,000 MG TABLET
- INVOKAMET 50 MG-500 MG TABLET
- INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKANA 100 MG TABLET
- INVOKANA 300 MG TABLET
- JARDIANCE 10 MG TABLET
- JARDIANCE 25 MG TABLET
- SYNJARDY 12.5 MG-1,000 MG TABLET
- SYNJARDY 12.5 MG-500 MG TABLET
- SYNJARDY 5 MG-1,000 MG TABLET
- SYNJARDY 5 MG-500 MG TABLET
- SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE

Details

Criteria	ST Criteria: Pending CMS Approval
-----------------	-----------------------------------

ST_RIVASTIGMINE_2019

Products Affected

Step 2:

- *rivastigmine 13.3 mg/24 hour transdermal patch*
- *rivastigmine 9.5 mg/24 hour transdermal patch*
- *rivastigmine 4.6 mg/24 hour transdermal patch*

Details

Criteria	
	Step Therapy requires trial of rivastigmine tablets in past 120 days.

ST_SMOKINGCESS_2019

Products Affected

Step 2:

- *bupropion hcl 150 mg tablet, 12 hr
sustained-release(smoking deterrent)*

Details

Criteria
Step therapy requires trial of Nicoderm patches in previous 120 days.

ULORIC_NVT 2015

Products Affected

Step 2:

- *febuxostat 40 mg tablet*
- *febuxostat 80 mg tablet*
- ULORIC 40 MG TABLET
- ULORIC 80 MG TABLET

Details

Criteria
Step Therapy requires trial of allopurinol in previous 120 days.

URINARY ANTISPASMODICS_NVT

Products Affected

Step 2:

- *darifenacin er 15 mg tablet, extended release 24 hr*
- *darifenacin er 7.5 mg tablet, extended release 24 hr*
- OXYTROL 3.9 MG/24 HR TRANSDERMAL PATCH
- TOVIAZ 4 MG TABLET, EXTENDED RELEASE
- TOVIAZ 8 MG TABLET, EXTENDED RELEASE

Details

Criteria	Step Therapy requires trial of solifenacin OR Myrbetriq in previous 120 days.
-----------------	---

ZADITOR OTC (CCHP2017)

Products Affected

Step 2:

- *olopatadine 0.1 % eye drops*

Step 3:

- *olopatadine 0.2 % eye drops*
- PAZEO 0.7 % EYE DROPS

Details

Criteria	Step Therapy requires trial of OTC zaditor/ketotifen for olopatadine ophth soln. Trial of olopatadine 1 mg/ml ophth soln required for olopatadine 2 mg/ml and PAZEO
-----------------	---

ZIOPTAN_NVT

Products Affected

Step 2:

- ZIOPTAN (PF) 0.0015 % EYE DROPS
IN A DROPPERETTE

Details

Criteria
Step Therapy requires trial of latanoprost.

2020 Chinese Community Health Plan Senior Program (HMO)

Step Therapy Criteria
Updated 8/2020

INDEX

A

acyclovir 5 % topical ointment	1
ALPHAGAN P 0.1 % EYE DROPS	2
AMITIZA 24 MCG CAPSULE.....	17
AMITIZA 8 MCG CAPSULE.....	17
APLENZIN 174 MG TABLET,EXTENDED RELEASE	5
APLENZIN 348 MG TABLET,EXTENDED RELEASE	5
APLENZIN 522 MG TABLET,EXTENDED RELEASE	5

B

BECONASE AQ 42 MCG (0.042 %) NASAL SPRAY	14
BESIVANCE 0.6 % EYE DROPS,SUSPENSION	15
bupropion hcl 150 mg tablet,12 hr sustained- release(smoking deterrent).....	21

D

darifenacin er 15 mg tablet,extended release 24 hr	23
darifenacin er 7.5 mg tablet,extended release 24 hr	23
DESVENLAFAXINE ER 100 MG TABLET,EXTENDED RELEASE 24 HR	4
DESVENLAFAXINE ER 50 MG TABLET,EXTENDED RELEASE 24 HR	4
DESVENLAFAXINE FUMARATE ER 100 MG TABLET, EXTENDED RELEASE 24 HR.....	4
DESVENLAFAXINE FUMARATE ER 50 MG TABLET, EXTENDED RELEASE 24 HR.....	4
DEXILANT 30 MG CAPSULE, DELAYED RELEASE	7
DEXILANT 60 MG CAPSULE, DELAYED RELEASE	7
DIFICID 200 MG TABLET	8
donepezil 10 mg disintegrating tablet	6
donepezil 5 mg disintegrating tablet	6

duloxetine 40 mg capsule,delayed release ..	4
---	---

E

EMSAM 12 MG/24 HR TRANSDERMAL 24 HOUR PATCH	4
EMSAM 6 MG/24 HR TRANSDERMAL 24 HOUR PATCH	4
EMSAM 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH	4
epinephrine 0.15 mg/0.15 ml auto-injector (for 33 to 66 lb patients).....	3
epinephrine 0.3 mg/0.3 ml injection, injector-auto	3
ESTRING 2 MG (7.5 MCG/24 HOUR) VAGINAL RING.....	11

F

febuxostat 40 mg tablet.....	22
febuxostat 80 mg tablet.....	22
FEMRING 0.05 MG/24 HR VAGINAL ..	11
FEMRING 0.1 MG/24 HR VAGINAL	11
FETZIMA 120 MG CAPSULE,EXTENDED RELEASE.....	4
FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK.....	4
FETZIMA 20 MG CAPSULE,EXTENDED RELEASE.....	4
FETZIMA 40 MG CAPSULE,EXTENDED RELEASE.....	4
FETZIMA 80 MG CAPSULE,EXTENDED RELEASE.....	4
fluvoxamine er 100 mg capsule,extended release 24 hr	4
fluvoxamine er 150 mg capsule,extended release 24 hr	4

G

gatifloxacin 0.5 % eye drops.....	15
-----------------------------------	----

I

INVOKAMET 150 MG-1,000 MG TABLET	19
INVOKAMET 150 MG-500 MG TABLET	19

2020 Chinese Community Health Plan Senior Program (HMO)

Step Therapy Criteria

Updated 8/2020

INVOKAMET 50 MG-1,000 MG TABLET	19
INVOKAMET 50 MG-500 MG TABLET	19
INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE	19
INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE	19
INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE	19
INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE	19
INVOKANA 100 MG TABLET	19
INVOKANA 300 MG TABLET	19

J

JANUMET 50 MG-1,000 MG TABLET ...	9
JANUMET 50 MG-500 MG TABLET	9
JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE	9
JANUMET XR 50 MG-1,000 MG TABLET,EXTENDED RELEASE	9
JANUMET XR 50 MG-500 MG TABLET,EXTENDED RELEASE	9
JANUVIA 100 MG TABLET	9
JANUVIA 25 MG TABLET	9
JANUVIA 50 MG TABLET	9
JARDIANCE 10 MG TABLET.....	19
JARDIANCE 25 MG TABLET.....	19

K

KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE	9
KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE	9
KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE	9

L

LINZESS 145 MCG CAPSULE.....	17
LINZESS 290 MCG CAPSULE.....	17
LINZESS 72 MCG CAPSULE.....	17

M

MARPLAN 10 MG TABLET	4
mometasone 50 mcg/actuation nasal spray	14
MOVANTIK 12.5 MG TABLET	17
MOVANTIK 25 MG TABLET	17

O

olopatadine 0.1 % eye drops	24
olopatadine 0.2 % eye drops	24
OMNARIS 50 MCG NASAL SPRAY.....	14
ONGLYZA 2.5 MG TABLET	9
ONGLYZA 5 MG TABLET	9
OXYTROL 3.9 MG/24 HR TRANSDERMAL PATCH	23
OZEMPIC 0.25 MG OR 0.5 MG (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR.....	12
OZEMPIC 1 MG/DOSE (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR ..	12

P

PANCREAZE 10,500 UNIT-35,500 UNIT- 61,500 UNIT CAPSULE,DELAYED RELEASE.....	16
PANCREAZE 16,800 UNIT-56,800 UNIT- 98,400 UNIT CAPSULE,DELAYED RELEASE	16
PANCREAZE 2,600 UNIT-6,200 UNIT- 10,850 UNIT CAPSULE,DELAYED RELEASE	16
PANCREAZE 21,000 UNIT-54,700 UNIT- 83,900 UNIT CAPSULE,DELAYED RELEASE	16
PANCREAZE 4,200 UNIT-14,200 UNIT- 24,600 UNIT CAPSULE,DELAYED RELEASE	16
PAZEO 0.7 % EYE DROPS.....	24
PERTZYE 16,000 UNIT-57,500 UNIT- 60,500 UNIT CAPSULE,DELAYED RELEASE	16
PERTZYE 24,000-86,250-90,750 UNIT CAPSULE,DELAYED RELEASE	16
PERTZYE 4,000 UNIT-14,375 UNIT- 15,125 UNIT CAPSULE,DELAYED RELEASE	16
PERTZYE 8,000 UNIT-28,750 UNIT- 30,250 UNIT CAPSULE,DELAYED RELEASE	16
PEXEVA 10 MG TABLET	4
PEXEVA 20 MG TABLET	4
PEXEVA 30 MG TABLET	4

2020 Chinese Community Health Plan Senior Program (HMO)

Step Therapy Criteria
Updated 8/2020

PEXEVA 40 MG TABLET	4	SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE	19
PREMARIN 0.625 MG/GRAM VAGINAL CREAM	11	SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE	19
Q		T	
QNASL 40 MCG/ACTUATION NASAL AEROSOL SPRAY	14	TOVIAZ 4 MG TABLET,EXTENDED RELEASE	23
QNASL 80 MCG/ACTUATION NASAL AEROSOL SPRAY	14	TOVIAZ 8 MG TABLET,EXTENDED RELEASE	23
R		TRINTELLIX 10 MG TABLET	4
RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SOLUTION.....	17	TRINTELLIX 20 MG TABLET	4
RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SYRINGE	17	TRINTELLIX 5 MG TABLET	4
RELISTOR 8 MG/0.4 ML SUBCUTANEOUS SYRINGE	17	TRULICITY 0.75 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR ..	12
RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE.....	10	TRULICITY 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR ..	12
rivastigmine 13.3 mg/24 hour transdermal patch.....	20	U	
rivastigmine 4.6 mg/24 hour transdermal patch.....	20	ULORIC 40 MG TABLET	22
rivastigmine 9.5 mg/24 hour transdermal patch.....	20	ULORIC 80 MG TABLET	22
RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE....	18	V	
RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE....	18	VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR.....	12
RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE....	18	VIIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK.....	4
RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE....	18	VIIIBRYD 10 MG TABLET	4
S		VIIIBRYD 20 MG TABLET	4
STIOLTO RESPIMAT 2.5 MCG-2.5 MCG/ACTUATION SOLUTION FOR INHALATION.....	13	VIIIBRYD 40 MG TABLET	4
SYNJARDY 12.5 MG-1,000 MG TABLET	19	Z	
SYNJARDY 12.5 MG-500 MG TABLET	19	ZENPEP 10,000 UNIT-32,000 UNIT- 42,000 UNIT CAPSULE,DELAYED RELEASE	16
SYNJARDY 5 MG-1,000 MG TABLET .	19	ZENPEP 15,000 UNIT-47,000 UNIT- 63,000 UNIT CAPSULE,DELAYED RELEASE	16
SYNJARDY 5 MG-500 MG TABLET	19	ZENPEP 20,000 UNIT-63,000 UNIT- 84,000 UNIT CAPSULE,DELAYED RELEASE	16
SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE	19	ZENPEP 25,000 UNIT-79,000 UNIT- 105,000 UNIT CAPSULE,DELAYED RELEASE	16
SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE	19	ZENPEP 3,000 UNIT-10,000 UNIT-14,000 UNIT CAPSULE,DELAYED RELEASE	16

2020 Chinese Community Health Plan Senior Program (HMO)

Step Therapy Criteria
Updated 8/2020

ZENPEP 40,000 UNIT-126,000 UNIT-
168,000 UNIT CAPSULE,DELAYED
RELEASE 16
ZENPEP 5,000 UNIT-17,000 UNIT-24,000
UNIT CAPSULE,DELAYED RELEASE
..... 16

ZETONNA 37 MCG/ACTUATION
NASAL HFA INHALER..... 14
ZIOPTAN (PF) 0.0015 % EYE DROPS IN
A DROPPERETTE..... 25